IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC
Non-squamous Cell Salivary Gland Carcinoma
Xencor, Inc.monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Non-squamous Cell Salivary Gland Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab VM Oncology, LLC | Phase 2 | B |
ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166 Klus Pharma Inc. | Phase 1/2 | CCC |
BENZOIC ACID, 4-((4-AMINO-3-(4-CYCLOHEXYL-1-PIPERAZINYL)-9,10-DIHYDRO-9,10-DIOXO-1-ANTHRACENYL)AMINO)- VM Oncology, LLC | Phase 1/2 | CCC |
cc-5013 National Cancer Institute (NCI) | Phase 1 | CC |
Recombinant Fowlpox-Gm-Csf National Cancer Institute (NCI) | Phase 1 | CC |
View all 13 →
Same molecule, other indications
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →